News

A University of Southern California researcher has received a $6.9 million U.S. government grant to continue her work on lung cell regeneration as a way of treating such diseases as pulmonary fibrosis and chronic obstructive pulmonary disease. Dr. Zea Borok of the university’s Keck School of Medicine received the seven-year grant under the National Heart, Lung, and…

Managing lung cancer in idiopathic pulmonary fibrosis patients is difficult, largely because standard lung cancer treatments create a risk of IPF exacerbations and patients dying early. An Italian study that covered four patients suggests that Boehringer Ingelheim’s Ofev (nintedanib) could be an answer. The research, “Lung Cancer in Patients with…

Clinical trials of idiopathic pulmonary fibrosis (IPF) therapies should include measures that reflect patients’ views of the success of treatments, Columbia University Medical Center researchers contend. In particular, the trials should add reduction in respiratory-related hospitalizations to their measurement tool kit, the team said. Patients’ views of treatment success could influence…

The European Commission (EC) recently approved a new formulation of Esbriet (pirfenidone) tablets for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF). According to Roche, Esbriet’s developer, the new tablet formulation will reduce the number of pills patients need to take throughout the day, offering patients an easier…

Supplemental oxygen during exercise can improve pulmonary fibrosis patients’ breathing and workout capabilities, according to a report in the journal Respirology. A key feature of idiopathic pulmonary fibrosis (IPF) is higher levels of damaging oxygen oxidants, or substances that oxidize other substances. These compounds trigger tissue scarring known as…